Weatherall David J
Weatherall Institute of Molecular Medicine, University of Oxford, John Radcliffe Hospital, Headington, Oxford, OX3 9DS, UK.
Ann N Y Acad Sci. 2005;1054:11-7. doi: 10.1196/annals.1345.002.
The thalassemias occur at some of their highest frequencies in the developing countries, particularly those of Asia. In many countries, facilities for the control of these conditions are extremely limited. Although a great deal can be done to help the situation by developing further North-South and South-South partnerships for disseminating better practice, the major problem for the future lies in the unwillingness of governments and international health agencies to accept that the thalassemias present a health burden comparable to that of other major diseases in the developing countries. However, preliminary analyses suggest that, at least in the case of Asia, this is not true. Further work of this nature, together with more detailed frequency and economic data, are required to provide solid evidence for the health burden posed by thalassemia in the developing world. Unless this is done, the large populations of patients with thalassemia in these countries will continue to be neglected.
地中海贫血症在发展中国家的发病率处于最高水平,尤其是在亚洲国家。在许多国家,控制这些病症的设施极为有限。尽管通过进一步发展南北和南南伙伴关系以传播更佳做法能够在很大程度上改善这种状况,但未来的主要问题在于政府和国际卫生机构不愿承认地中海贫血症给发展中国家带来的健康负担与其他主要疾病相当。然而,初步分析表明,至少在亚洲情况并非如此。需要开展更多此类性质的工作,并获取更详细的发病率和经济数据,以便为地中海贫血症给发展中世界造成的健康负担提供确凿证据。除非做到这一点,这些国家大量的地中海贫血症患者将继续被忽视。